A review of targeted screening for prostate cancer: Introducing the IMPACT Study

BJU International

Volumn 99, Issue 6, 2007, Pages 1350-1355

  Mitra, Anita V ^a   Bancroft, Elizabeth K ^a   Eeles, Rosalind A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

BRCA1; BRCA2; IMPACT study; Prostate cancer; Screening

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER RISK; CANCER SCREENING; CAUCASIAN; FAMILY HISTORY; GENE MUTATION; GROUPS BY AGE; HUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEOMICS; RACE; SHORT SURVEY; ADULT; AGED; BLOOD; CEREBROSPINAL FLUID; CLINICAL TRIAL; FAMILY HEALTH; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROSTATE TUMOR; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE;

ADULT; AGED; FAMILY HEALTH; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 34447326479     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06759.x     Document Type: Short Survey

References (33)

1. Prorok PC, Andriole GL, Bresalier RS et al. Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000 21 (Suppl. 273S 309S
2. Roobol MJ, Schroder FH, Kranse R ERSPC Rotterdam. A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam). Prostate 2006 66 : 604 12
3. Donovan J, Hamdy F, Neal D et al. ProtecT Study Group. Prostate testing for cancer treatment (ProtecT) feasibility study. Health Technol Assess 2003 7 : 1 88
4. Gosselaar C, Roobol MJ, Roemeling S et al. Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam. Prostate 2006 66 : 625 31
5. Catalona WJ, Loeb S, Han M. Viewpoint: expanding prostate cancer screening. Ann Intern Med 2006 144 : 441 3
6. Crawford ED, Pinsky PF, Chia D et al. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial. J Urol 2006 175 : 1286 90
7. Schroder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R. Prostate-specific antigen-based early detection of prostate cancer - validation of screening without rectal examination. Urology 2001 57 : 83 90
8. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per millilitre N Engl J Med 2004 350 : 2239 46
9. Gronberg H, Damber L, Damber JE. Studies of genetic factors in prostate cancer in a twin population. J Urol 1994 152 : 1484 9
10. Edwards SM, Eeles RA. Unravelling the genetics of prostate cancer. Am J Med Genet C Semin Med Genet 2004 129 : 65 73
11. Bruner D, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer 2003 107 : 797 803
12. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992 89 : 3367 71
13. Gronberg H, Damber L, Damber JE, Iselius L. Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Am J Epidemiol 1997 146 : 552 7
14. Cui J, Staples MP, Hopper JL, English DR, McCredie MR, Giles GG. Segregation analysis of 1,476 population-based Australian families affected by prostate cancer. Am J Hum Genet 2001 68 : 1207 18
15. Sigurdsson S, Thorlacius S, Tomasson J et al. BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 1997 75 : 758 61
16. Thompson D, Easton D Breast Cancer Linkage Consortium. Variation in cancer risks by mutation position, in BRCA 2 mutation carriers. Am J Hum Genet 2001 68 : 410 9
17. Thompson D, Easton D Breast Cancer Linkage Consortium. Cancer incidence in BRCA 1 mutation carriers. J Natl Cancer Inst 2002 94 : 1358 65
18. Lehrer S, Fodor F, Stock RG et al. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer 1998 78 : 771 3
19. Nastiuk KL, Mansukhani M, Terry MB et al. Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate 1999 40 : 172 7
20. Hubert A, Peretz T, Manor O et al. The Jewish Ashkenazi founder mutation in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet 1999 65 : 921 4
21. Vazina A, Baniel J, Yaacobi Y et al. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer in Israel. Br J Cancer 2000 83 : 463 6
22. Giusti RM, Rutter JL, Duray PH et al. A twofold increase in BRCA mutations related PC among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet 2003 40 : 787 92
23. Edwards SM, Kote-Jarai Z, Meitz J et al. Two per cent of men with early onset prostate cancer harbour germline mutations in the BRCA 2 gene. Am J Hum Genet 2003 72 : 1 12
24. Gronberg H, Ahman AK, Emanuelsson M, Bergh A, Damber JE, Borg A. BRCA2 mutation in a family with hereditary prostate cancer. Genes Chromosomes Cancer 2001 30 : 299 301
25. McWhorter WP, Hernandez AD, Meikle AW et al. A screening study of prostate cancer in high risk families. J Urol 1992 148 : 826 8
26. Narod SA, Dupont A, Cusan L et al. The impact of family history on early detection of prostate cancer. Nat Med 1995 1 : 99 101
27. Matikainen MP, Schleutker J, Morsky P, Kallioniemi OP, Tammela TL. Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families. Clin Cancer Res 1999 5 : 1275 9
28. Makinen T, Tammela TL, Stenman UH et al. Family history and prostate cancer screening with prostate-specific antigen. J Clin Oncol 2002 20 : 2658 63
29. Valeri A, Cormier L, Moineau MP et al. Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives. J Urol 2002 168 : 483 7
30. Edwards S, Hope Q, Meitz J et al. Prostate cancer in BRCA2 mutation carriers: mechanisms of tumorigenicity and prediction for a much poorer prognosis. AACR Meeting Abstracts April 2005 : 747
31. Catalona WJ, Antenor JA, Roehl KA, Moul JW. Screening for prostate cancer in high risk populations. J Urol 2002 168 : 1980 4
32. Uzzo RG, Pinover WH, Horwitz EM et al. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digital rectal examination. Urology 2003 61 : 754 9
33. Horsburgh S, Matthew A, Bristow R, Trachtenberg J. Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic. Prostate 2005 65 : 124 9